News articles about Summit Therapeutics (NASDAQ:SMMT) have been trending positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Summit Therapeutics earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.2903872368956 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of equities research analysts recently weighed in on the stock. ValuEngine downgraded shares of Summit Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Zacks Investment Research upgraded shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Summit Therapeutics in a report on Thursday, December 7th. Canaccord Genuity reiterated a “buy” rating on shares of Summit Therapeutics in a report on Monday, October 16th. Finally, Oppenheimer restated a “buy” rating and set a $24.00 target price on shares of Summit Therapeutics in a report on Monday, October 16th. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $21.20.
Shares of Summit Therapeutics (SMMT) traded up $0.25 on Monday, hitting $12.68. 42,500 shares of the stock traded hands, compared to its average volume of 41,233. Summit Therapeutics has a 52 week low of $8.80 and a 52 week high of $16.86. The company has a market capitalization of $175.54, a price-to-earnings ratio of -126.80 and a beta of 0.37.
WARNING: This piece of content was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://baseballnewssource.com/markets/summit-therapeutics-smmt-receives-media-sentiment-rating-of-0-25/1819312.html.
Summit Therapeutics Company Profile
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.